Opportunity Information: Apply for RFA CA 24 015
The National Institutes of Health (NIH), through the National Cancer Institute (NCI), is offering a discretionary grant opportunity (RFA-CA-24-015) to support revision applications from currently funded NCI P30 Centers. This funding is specifically for centers that already hold an active P30 award and want to submit a revision (formerly called a competing revision) that meaningfully extends or strengthens the parent P30-supported work. The central idea is to speed up progress on the parent center's research by adding a new technical approach, tool, or instrument that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program. The NOFO is listed as "Clinical Trial Optional," meaning the proposed revision work may include a clinical trial component if appropriate, but it is not required.
The goal of the program is not simply to add incremental capability, but to use IMAT-developed technologies in a way that expands the original research questions within specific projects or otherwise accelerates the pace, rigor, or reach of the parent study. A key emphasis is on incentivizing independent validation of emerging IMAT technologies and moving them closer to being broadly usable by the cancer research community. In practice, this means the revision should help demonstrate that an IMAT-derived method or instrument is reliable, fit-for-purpose, and ready to be applied in real cancer research settings, rather than remaining at an early prototype stage. The NOFO also reflects the broader IMAT mission of promoting interdisciplinary collaboration, with the expectation that teams will bridge technology development and cancer biology, clinical research, or population science in ways that enable new discovery.
Eligibility is broad across many U.S.-based organization types, but the opportunity is fundamentally anchored to NCI P30 center awardees because it solicits revisions to existing P30 grants. Eligible applicant organizations include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (when not institutions of higher education); for-profit organizations other than small businesses; and small businesses. The NOFO also highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, and Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), along with faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Foreign participation is explicitly restricted. Non-domestic (non-U.S.) entities are not eligible to apply, non-domestic components of U.S. organizations are not eligible, and foreign components (as defined by NIH policy) are not allowed under this announcement. In other words, the applicant organization and the supported work need to be fully domestic under NIH definitions.
Key administrative details include a listed CFDA number of 93.394 and an original application closing date of 2024-10-01. The award ceiling is $150,000. The opportunity was created on 2023-11-28. While the number of expected awards is not specified in the provided listing, the budget cap and revision-only scope signal a targeted, add-on funding mechanism intended to rapidly integrate and validate IMAT-supported technologies within existing P30 center structures, rather than launching entirely new standalone projects.Apply for RFA CA 24 015
- The National Institutes of Health in the education, health sector is offering a public funding opportunity titled "Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P30 Clinical Trial Optional)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.394.
- This funding opportunity was created on 2023-11-28.
- Applicants must submit their applications by 2024-10-01. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Each selected applicant is eligible to receive up to $150,000.00 in funding.
- Eligible applicants include: State governments, County governments, City or township governments, Special district governments, Independent school districts, Public and State controlled institutions of higher education, Native American tribal governments (Federally recognized), Public housing authorities/Indian housing authorities, Native American tribal organizations (other than Federally recognized tribal governments), Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education, Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education, Private institutions of higher education, For-profit organizations other than small businesses, Small businesses, Others.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: NIH/NCI RFA-CA-24-015 (P30 Center Revision to Integrate IMAT Technologies)
What is this funding opportunity?
This is a discretionary grant opportunity from the National Institutes of Health (NIH), through the National Cancer Institute (NCI), identified as RFA-CA-24-015. It supports revision applications to currently funded NCI P30 Centers.
Who is this opportunity intended for?
It is intended specifically for organizations that already hold an active NCI P30 Center award and want to submit a revision (formerly called a competing revision) to strengthen or extend the work supported by the parent P30 grant.
Is this a new standalone grant or an add-on to an existing award?
This opportunity is for revisions to existing NCI P30 grants, not for brand-new standalone projects. The proposed work should meaningfully extend or strengthen the parent P30-supported research.
What is the main purpose of the revision funding?
The central purpose is to accelerate progress on the parent center's research by adding a new technical approach, tool, or instrument that was developed with support from NCI's Innovative Molecular Analysis Technologies (IMAT) program.
What kinds of additions does NCI want to see in a revision application?
The revision should integrate an IMAT-developed technology in a way that expands the original research questions within specific projects or otherwise accelerates the pace, rigor, or reach of the parent study. The intent is more than adding incremental capability.
Is incremental improvement enough for this NOFO?
No. The stated goal is not simply to add incremental capability. The expectation is that IMAT-developed technologies are used in a way that meaningfully expands what the parent P30 research can do or speeds up and strengthens the science.
What does the opportunity emphasize about IMAT technologies?
A key emphasis is on incentivizing independent validation of emerging IMAT technologies and moving them closer to broad usability for the cancer research community. The revision should help show that the IMAT-derived method or instrument is reliable, fit-for-purpose, and ready for real cancer research settings (not stuck at an early prototype stage).
What does "Clinical Trial Optional" mean here?
"Clinical Trial Optional" means the proposed revision work may include a clinical trial component if it is appropriate for the aims, but a clinical trial is not required under this announcement.
Does the revision have to include a clinical trial?
No. A clinical trial may be included if appropriate, but it is not required.
How does this opportunity relate to interdisciplinary collaboration?
The NOFO reflects the broader IMAT mission of promoting interdisciplinary collaboration. Teams are expected to bridge technology development with cancer biology, clinical research, or population science in ways that enable new discovery.
What organizations are eligible to apply?
Eligibility includes many U.S.-based organization types, but applicants must be active NCI P30 Center awardees since the mechanism is a revision to an existing P30. Eligible organization categories listed include state, county, and local governments; special district governments; independent school districts; public and state-controlled institutions of higher education; private institutions of higher education; federally recognized Native American tribal governments; tribal organizations that are not federally recognized; public housing authorities/Indian housing authorities; nonprofits with and without 501(c)(3) status (when not institutions of higher education); for-profit organizations other than small businesses; and small businesses.
Are specific institution types called out as eligible?
Yes. The NOFO highlights additional eligible categories such as Historically Black Colleges and Universities (HBCUs), Hispanic-serving institutions, Tribally Controlled Colleges and Universities (TCCUs), Alaska Native and Native Hawaiian Serving Institutions, Asian American Native American Pacific Islander Serving Institutions (AANAPISIs), as well as faith-based or community-based organizations, eligible federal agencies, regional organizations, and U.S. territories or possessions.
Can a non-U.S. organization apply?
No. Non-domestic (non-U.S.) entities are not eligible to apply under this announcement.
Can a U.S. organization include a non-domestic component?
No. Non-domestic components of U.S. organizations are not eligible.
Are foreign components allowed under NIH policy for this opportunity?
No. Foreign components (as defined by NIH policy) are not allowed under this announcement.
What is the award ceiling (maximum amount) for this opportunity?
The award ceiling listed is $150,000.
Is the number of awards known?
The number of expected awards is not specified in the provided listing.
What is the CFDA number associated with this opportunity?
The listed CFDA number is 93.394.
What is the application closing date provided?
The original application closing date listed is 2024-10-01.
When was this opportunity created?
The opportunity was created on 2023-11-28.
What is the overall funding approach suggested by the description?
Based on the revision-only scope and the $150,000 budget cap, this appears to be a targeted add-on funding mechanism designed to rapidly integrate and validate IMAT-supported technologies within existing P30 center structures, rather than launching new standalone projects.
What kind of outcomes is NCI trying to promote through this revision funding?
The described outcomes include faster progress on the parent center's research, stronger rigor and reach of the parent studies, and independent validation that helps IMAT-derived tools and instruments become broadly usable by the cancer research community.
Browse more opportunities from the same category: Education, Health
Next opportunity: EducationUSA Professional College Counselor Network Program
Previous opportunity: Clinical Observational (CO) Studies in Musculoskeletal, Rheumatic, and Skin Diseases (R01 Clinical Trial Not Allowed)
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for RFA CA 24 015
Applicants also applied for:
Applicants who have applied for this opportunity (RFA CA 24 015) also looked into and applied for these:
| Funding Opportunity |
|---|
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (P50 Clinical Trial Optional) Apply for RFA CA 24 014 Funding Number: RFA CA 24 014 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 24 011 Funding Number: RFA CA 24 011 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Revision Applications for Incorporation of Novel NCI- Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional) Apply for RFA CA 24 013 Funding Number: RFA CA 24 013 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (R01 Clinical Trial Optional) Apply for RFA CA 24 012 Funding Number: RFA CA 24 012 Agency: National Institutes of Health Category: Education, Health Funding Amount: $150,000 |
| Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed) Apply for RFA CA 24 009 Funding Number: RFA CA 24 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Providing Research Education Experiences to Enhance Inclusivity for a Diverse Substance Use and Addiction Scientific Workforce (R25 Clinical Trials Not Allowed) Apply for PAR 24 048 Funding Number: PAR 24 048 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Addressing Health and Health Care Disparities among Sexual and Gender Minority Populations (R01 - Clinical Trials Optional) Apply for PAR 24 077 Funding Number: PAR 24 077 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Adoptive Cellular Therapy Network (Can-ACT) for Pediatric Cancers (UG3/UH3 Clinical Trial Required) Apply for RFA CA 24 021 Funding Number: RFA CA 24 021 Agency: National Institutes of Health Category: Education, Health Funding Amount: $900,000 |
| Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 009 Funding Number: RFA DA 25 009 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Interplay of Autophagy Regulated Cell Death and HIV Pathogenesis in Substance Use Disorders (R21 Clinical Trial Not Allowed) Apply for RFA DA 25 010 Funding Number: RFA DA 25 010 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Integrated Functional Mapping and Molecular Profiling of Cell Ensembles Encoding the Effects of Addictive Substances in Rodents (R01 Clinical Trial Not Allowed) Apply for RFA DA 25 023 Funding Number: RFA DA 25 023 Agency: National Institutes of Health Category: Education, Health Funding Amount: $700,000 |
| Assessment of Climate at Institutions (ACt) Award (RC2 - Clinical Trial Not Allowed) Apply for PAR 24 038 Funding Number: PAR 24 038 Agency: National Institutes of Health Category: Education, Health Funding Amount: $250,000 |
| Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowed) Apply for PAR 24 088 Funding Number: PAR 24 088 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional) Apply for RFA CA 24 016 Funding Number: RFA CA 24 016 Agency: National Institutes of Health Category: Education, Health Funding Amount: $275,000 |
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 24 018 Funding Number: RFA CA 24 018 Agency: National Institutes of Health Category: Education, Health Funding Amount: $600,000 |
| Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional) Apply for RFA CA 24 017 Funding Number: RFA CA 24 017 Agency: National Institutes of Health Category: Education, Health Funding Amount: $300,000 |
| Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional) Apply for RFA CA 24 019 Funding Number: RFA CA 24 019 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required) Apply for PAR 24 085 Funding Number: PAR 24 085 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required) Apply for PAR 24 072 Funding Number: PAR 24 072 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
| Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional) Apply for RFA DA 25 028 Funding Number: RFA DA 25 028 Agency: National Institutes of Health Category: Education, Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "RFA CA 24 015", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.